Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany
暂无分享,去创建一个
D. Fliser | V. Calice-Silva | R. Pecoits-Filho | H. Reichel | Z. Massy | K. McCullough | D. Muenz | F. Tillmann | B. Bieber | J. Duttlinger | J. Budden | C. Quinn | J. Golden | B. Robinson | A. R. de Arellano | V. Cálice-Silva
[1] H. Tighiouart,et al. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] B. Williams,et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial , 2019, The Lancet.
[3] J. Carrero,et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.
[4] D. Fliser,et al. Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care , 2019, Journal of clinical hypertension.
[5] M. Freeman,et al. Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN , 2018, ESC heart failure.
[6] Steven D. Woods,et al. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. , 2017, The American journal of medicine.
[7] D. Fliser,et al. The CKD Outcomes and Practice Patterns Study (CKDopps): Rationale and Methods. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] M. Cope,et al. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia , 2016, Journal of cardiovascular pharmacology and therapeutics.
[9] G. Bakris,et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors , 2015, European journal of heart failure.
[10] N. Oestreicher,et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. , 2015, The American journal of managed care.
[11] M. Freeman,et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. , 2015, JAMA.
[12] G. Bakris,et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. , 2015, The New England journal of medicine.
[13] D. Fliser,et al. Implementation and first results of a German chronic kidney disease registry. , 2013, Clinical nephrology.
[14] Di Xie,et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. , 2006, The New England journal of medicine.
[15] B. Palmer. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.